



## **Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference**

October 2, 2024

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8<sup>th</sup> Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024.

The fireside chat will be webcast live and may be accessed [here](#) or by visiting Madrigal's website's Investor Relations Events [page](#). A replay of the webcast will be available after the event.

### **About Madrigal Pharmaceuticals**

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR- $\beta$  agonist designed to target key underlying causes of NASH. For more information, visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

### **Investor Contact**

Tina Ventura, [IR@madrigalpharma.com](mailto:IR@madrigalpharma.com)

### **Media Contact**

Christopher Frates, [media@madrigalpharma.com](mailto:media@madrigalpharma.com)



Source: Madrigal Pharmaceuticals, Inc.